The influence of tamoxifen treatment on the oestrogen receptor in metachronous contralateral breast cancer

British Journal of Cancer

Volumn 88, Issue 5, 2003, Pages 707-710

  Kaas, R ^a   Peterse, J L ^a   Hart, A A M ^a   Voogd, A C ^b   Rutgers, E J T ^a   Van Leeuwen, F E ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b Eindhoven Cancer Registry   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 0037430009     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600746     Document Type: Article

References (12)

1. American Society of Clinical Oncology (1997) Recommended breast cancer surveillance guidelines. J Olin Oncol 15: 2149-2156
2. Chlebowski RT, Collyar DE, Somerfield MR, Pfister DG for the ASCO working group (1999) ASCO technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. J Clin Oncol 17: 1939-1955
3. De Placido S, Gallo C, Marinelli A, Perrone F, Pagliarulo C, Petrella G et al. (1990) Steroid hormone receptor levels and adjuvant tamoxifen in early breast cancer. Breast Cancer Res and Treat 16: 111-11713
4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351: 1451-1467
5. Fisher B, Constantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM et al (1998) Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 90: 1371-1388
6. IBIS Investigators (2002) First results from the International Breast Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360: 817-824
7. Li CI, Malone KE, Weiss NS, Daling IR (2001) Tamoxifen therapy for primary breast cancer and risk of contralateral breast cancer. J Nat Cancer Inst. 93: 1008-1013
8. Loman N, Johansson O, Bendahl PO, Borg A, Ferno M, Olsson H (1998) Steroid receptors in hereditary breast carcinomas associated with BRCA 1 or BRCA 2 mutations or unknown susceptibility genes. Cancer 83: 310-319
9. O'Regan RM, Jordan VC (2002) The evaluation of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulatots. Oncology Lancet 3: 207-214
10. Radmacher MD, Simon R (2000) Estimation of tamoxifen's efficacy for preventing formation and growth of breast tumors. J Natl Cancer Inst 92: 48-53
11. Rutqvist LE, Cedermark B, Glas U, Mattsson A, Skoog L, Somell A et al (1991) Contralateral primary tumors in breast cancer. Patients in a randomised trial of adjuvant tamoxifen therapy. J Natl Cancer Inst 83: 1299-1306
12. Tarone RE, Chu KC (2002) The greater impact of menopause on ER- than ER+ breast cancer incidence: a possible explanation (United States). Cancer Causes Control 13: 7-14